Embedded Files
CRAFT YOUR BUSINESS, AND REDEFINE YOUR PERFORMANCE WITH DELVEINSIGHT!
Parkinson's disease Market Will Reflect Significant Growth Prospects During the Study Period [2017-2030], Anticipates DelveInsight
DelveInsight's "Parkinson's Disease Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Parkinson's Disease, historical and forecasted epidemiology as well as the Parkinson's Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Parkinson's Disease market size was USD 1837.90 million in 2017 in the 7MM. Among the 7 Major Markets, the United States accounted for the majority of the market size, with USD 941.13 million followed by Germany, which has the second-highest market size after the United States in 2017.
Some of the facts of the report
· Parkinson's Disease total prevalent population in the 7MM countries was observed to be 1,608,367 in 2017 and is growing at a CAGR of 0.54% for the study period [2017–2028].
· Parkinson's Disease total diagnosed prevalent population was 1,373,639 in 2017.
· Parkinson's Disease diagnosed prevalent population was assessed to be the highest for the United States that accounts for 44.29% of the total patient pool among the 7MM countries.
View Report: https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment
Request for Free sample Report: https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment
Key benefits of the report
1. Parkinson's Disease market report covers a detailed overview and comprehensive insight of the Parkinson's Disease Epidemiology and Parkinson's Disease market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Parkinson's Disease market report provides insights into the current and emerging Parkinson's Disease therapies.
3. Parkinson's Disease market report offers a global historical and forecasted market covering drug outreach in 7MM.
4. Parkinson's Disease market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Parkinson's Disease market.
"The age-specific prevalence data showed that the majority of the cases were diagnosed in the age-group of 65-84 years, followed by those aged 45-64 years in the 7MM countries."
View Report: https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment
Get a free sample page : https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment
There are currently no disease‐modifying drugs, but Parkinson's Disease treatments are used to offer major symptomatic relief of the motor symptoms. They offer little benefit clinically in terms of the nonmotor manifestations. The present Parkinson's Disease treatment options include surgery, medication, complementary and supportive therapies (such as diet, exercise, physical therapy, occupational therapy, and speech therapy). The approved medication therapies are categorized into seven groups that include Levodopa, Carbidopa‐levodopa infusion (Duodopa), Dopamine agonists, MAO B inhibitors, Catechol O‐methyltransferase (COMT) inhibitors, Anticholinergics and Amantadine. The drug to be used at the beginning of Parkinson's Disease treatment is either levodopa or a dopamine agonist. L‐Dopa, a natural precursor of dopamine that is transformed in the brain into dopamine.
Besides gene therapy, stem cell therapy have also shown a more effective Parkinson's Disease treatment option. Stem cell research in Parkinson's Disease is focusing on understanding nerve cells development and how healthy cells can be used to replace unhealthy brain cells.
View Report: https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment
Request for Free sample Report: https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment
The expected launch of emerging therapies is believed to create a positive impact on Parkinson's Disease market size in the upcoming years.
1. Apomorphine Infusion
2. Accordion Pill Carbidopa/Levodopa
3. APL–130277
4. P2B001
5. IPX203
6. LY03003
7. ABBV‐951
8. NTCELL Implantation
9. Nilotinib
10. VY‐AADC
And many others
The key Parkinson's Disease market players have the potential to create a significant positive shift in Parkinson's Disease Market Size. Some of the companies involved are:-
1. US WorldMeds LLC
2. Intec Pharma
3. Sunovion Pharma
4. Pharma Two B Ltd.
5. Impax Laboratories
6. Luye Pharma
7. AbbVie
8. Living Cell Technologies
9. Novartis
10. Neurocrine Biosciences
And many others
View Report: https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment
Get a free demo of the report: https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment
Table of Contents
1 Parkinson's Disease Key Insights
2 Executive Summary of Parkinson's Disease
3 Parkinson's Disease Market Overview at a Glance
4 Parkinson's Disease Case Reports
5 Parkinson's Disease Epidemiology and Patient Population
6 Country Wise-Epidemiology of Parkinson's Disease
6.1 The United States Epidemiology
6.2 EU5 Countries Epidemiology
6.2.1 Germany
6.2.2 France
6.2.3 Italy
6.2.4 Spain
6.2.5 The United Kingdom
6.3 Japan Epidemiology
7 Treatment and Management of Parkinson's Disease
8 Parkinson's Disease Unmet Needs
9 Parkinson's Disease Marketed Drugs
9.1 Istradefylline (KW-6002): Kyowa Kirin
9.2 Opicapone: BIAL
9.3 Gocovri: Adamas Pharmaceuticals
9.4 Xadago: Zambon SpA
9.5 Osmolex ER: Osmotica Pharmaceutical
9.6 Duopa (Duodopa, ABT-SLV187): AbbVie
9.7 Rytary: Impax Laboratories (Amneal Pharmaceuticals)
9.8 Inbrija: Acorda Therapeutics
9.9 Nuplazid: ACADIA Pharmaceuticals Inc.
10 Parkinson's Disease Emerging Drugs
10.1 Apomorphine Infusion: US WorldMeds LLC
10.2 Accordion Pill Carbidopa/Levodopa: Intec Pharma
10.3 P2B001: Pharma Two B Ltd.
10.4 IPX203: Impax Laboratories (Amneal Pharmaceuticals)
10.5 LY03003: Luye Pharma
10.6 ABBV-951: AbbVie
10.7 Allo iPS cell-derived dopamine neural progenitor: Sumitomo Dainippon Pharma
10.8 Solriamfetol (JZP-110): Jazz Pharmaceuticals
10.9 NBIb-1817 (VY-AADC): Neurocrine Biosciences/Voyager Therapeutics
10.10 AAV-GAD: MeiraGTx Limited
10.11 AXO-Lenti-PD (OXB-102): Axovant Sciences
10.12 ND0612: NeuroDerm
10.13 ITI-214: Intracellular Therapies
10.14 IRL752: Integrative Research Laboratories AB (IRLAB)
10.15 PR001: Prevail Therapeutics
10.16 ISC-hpNSC: International Stem Cell Corporation
11 7MM Parkinson's Disease Market Analysis
11.1 The United States Parkinson's Disease Market Size
11.2 EU-5 Parkinson's Disease Market Size
11.2.1 Germany Market Size
11.2.2 France Market Size
11.2.3 Italy Market Size
11.2.4 Spain Market Size
11.2.5 The United Kingdom Market Size
11.3 Japan Parkinson's Disease Market Size
12 Parkinson's Disease Market Drivers
13 Parkinson's Disease Market Barriers
14 SWOT Analysis of Parkinson's Disease
15 KOL Views
16 Parkinson's Disease Market Access and Reimbursement
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight
Request for Deatiled TOC: https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment
Other Links:
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Contact us
Ankit Nigam
info@delveinsight.com
+91-9650213330
Connect With Us at:
Get Free Sample Copy of Report at: https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment
Page updated
Report abuse